Eledon Pharmaceuticals, Inc.
ELDNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. Valued at $294.1M, ELDN is a micro-cap name in its sector. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Market Cap
$294.1M
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-5.27
EPS (TTM)
$-0.77
EPS (Fwd)
$-0.72
ROE
-72.7%
ROA
-35.1%
Cash
$111.1M
Total Debt
$555,000
Free CF
-$39.7M
52W Change
24.5%
Annual Financials
Cash vs Debt
Eledon Pharmaceuticals, Inc. holds $111.1M in cash against $555K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$39.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -72.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ELDN.